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Abstract
Background: Patients with type 2 diabetes are at an increased risk for disease and treatment related complications
after the initial approach of oral mono/dual antidiabetic therapy has failed. Data from clinical practice with respect
to this patient group are however scarce. Therefore we set up a registry in primary care documenting the course
and outcomes of this patient group.
Methods: Diabetes Treatment Patterns and Goal Achievement in Primary Diabetes Care (DiaRegis) is a prospective,
observational, German, multicenter registry including patients with type-2 diabetes in which oral mono/dual
antidiabetic therapy has failed. Data were recorded at baseline and will be prospectively documented during visits
at 6 ± 1, 12 ± 2 and 24 ± 2 months. The primary objective is to estimate the proportion of patients with at least 1
episode of severe hypoglycemia within one year.
Results: 313 primary care offices included 4,048 patients between June 2009 and March 2010 of which 3,810
patients fulfilled the in- and exclusion criteria. 46.7% of patients were female; patients had a median diabetes
duration of 5.5 years and most were obese with respect to BMI or waist circumference. Hb
A1c at baseline was 7.4%,
fasting plasma glucose 142 mg/dl and postprandial glucose 185 mg/dl. Co-morbidity in this patient population
was substantial with 17.9% having coronary artery disease, 14.4% peripheral neuropathy, 9.9% heart failure and
6.0% peripheral arterial disease. 68.6% of patients received oral monotherapy, 31.4% dual oral combination therapy.
The most frequent antidiabetic agent used as monotherapy was metformin (79.0%) followed by sulfonylureas
(14.8%).
Conclusions: DiaRegis is a large, prospective registry in primary diabetes care to document the course and
outcomes of patients with type-2 diabetes in which the initial approach of oral mono/dual antidiabetic therapy has
failed. The two year follow-up will allow for a prospective evaluation of these patients during multiple adjustments
of therapy.
Background
Patients with type 2 diabetes are at an increased risk for
disease and treatment related complications. This is par-
ticularly true at a point where patients are switched
from oral monotherapy, to combination drug therapies,
diabetes is usually more advanced, complicated by a
number of co-morbid disease conditions and the likeli-
hood of disease and treatment related complications is
increased. Intensive glucose control–in particular when
complex insulin strategies are used–is associated with a
5-fold increased risk for severe hypoglycemia, which
could induce harm in some patients [1].
The recent guideline of the German Diabetes Society
(Deutsche Diabetes Gesellschaft, DDG) recommends to
* Correspondence: diethelm.tschoepe@ruhr-uni-bochum.de
† Contributed equally
5Herz- und Diabeteszentrum Nordrhein-Westfalen in Bad Oeynhausen,
Universitätsklinik der Ruhr Universität, Bochum, Germany
Full list of author information is available at the end of the article
Bramlage et al. Cardiovascular Diabetology 2010, 9:53
http://www.cardiab.com/content/9/1/53
CARDIO
VASCULAR 
DIABETOLOGY
© 2010 Bramlage et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.combine metformin with a number of different oral
antidiabetic drugs or a GLP-1 analogue in patients
whose HbA1c remains ≥ 6.5% but is < 7.5% after 3-6
month of metformin monotherapy treatment (with
nutritional counselling and sports). Insulin should be
added if HbA1c is still ≥ 6.5% after 3-6 month treatment
with combination therapy or if HbA1c is ≥ 7.5% after the
initial metformin/other OAD monotherapy [2].
Of particular importance when optimizing pharma-
cotherapy is the balance between optimal blood glucose
adjustments (HbA1c, postprandial glucose) and the risk
of hypoglycemia, the potential increase in body weight
observed specifically with sulfonylureas, glinides and
insulin regimens.
HbA1c adjustment
The primary target of guideline recommended therapies
is the adjustment of HbA1c as the ultimate therapeutic
goal. Guidelines use HbA1c a sas u r r o g a t ei nal a c ko f
hard end points for most antidiabetic treatments [2].
This approach however is surprising since patients with
type 2 diabetes whose HbA1c was reduced from 8 to 7%
in the UKPDS (United Kingdom Prospective Diabetes
Study) did not exhibit a reduction in cardiovascular
events [3]. That HbA1c m a yo n l yb ea ni n c o m p l e t es u r -
rogate for cardiovascular endpoints was recently con-
firmed by the results of ACCORD (Action to Control
Cardiovascular Risk in Diabetes, [4]), ADVANCE
(Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation, [5])
a n dV A D T( V e t e r a n sA f f a i r sD i a b e t e sT r i a l )[ 6 ] .I tw a s
found that intensive blood sugar lowering had no signif-
icant benefit in terms of decreasing cardiovascular risk.
For new antidiabetic treatments the FDA issued guide-
lines requesting specific prospective analysis of the
submitted data to assess cardiovascular safety and gives
directions to the patient population to be entered in
terms of cardiovascular comorbidity [7].
Postprandial Glucose
This rise and fall of postprandial glucose level is
mediated by the first-phase insulin response, in which
large amounts of endogenous insulin are released,
usually within 10 min, in response to nutrient intake. In
individuals with type 2 diabetes, the first-phase insulin
response is severely diminished or absent, resulting in
persistently elevated postprandial glucose throughout
most of the day [8]. Although there is still some debate
whether postprandial glucose is a proper measure of
overall glucose control, a number of studies have
demonstrated a close correlation between postprandial
glucose and glycaemic control [9-14]. Regardless of
whether postprandial glucose is a better predictor of
HbA1c than fasting/preprandial glucose, most researchers
agree that the best predictor of HbA1c is mean blood
glucose, which is a composite of both fasting/prepran-
dial and postprandial glucose. It is reasonable to assume,
that achieving near-normal postprandial glucose levels
without risk for hypoglycemia is essential to achieving
overall glycaemic control.
Hypoglycemia
Patients with blood glucose values less than 2.22 mmol/l
are regarded, irrespective of symptoms, as being hypo-
glycaemic. Values between 2.22 and 2.78 mmol/l are
still regarded as hypoglycaemic if cerebral symptoms of
low blood glucose are evident. With many antidiabetic
drugs such as sulfonylureas or insulin intensified blood
glucose lowering has been associated with an increase in
the rate of severe hypoglycemia (Figure 1) [4-6,15].
Severe hypoglycemia has been made responsible for
excess deaths in the ACCORD trial [16]. Nineteen of
the 41 excess deaths from cardiovascular causes in the
study were attributed to “unexpected or presumed cardi-
ovascular disease,” which may plausibly be related to or
may have been precipitated by hypoglycemia and mis-
classified as having a cardiovascular cause. Combination
therapies, such as a sulfonylurea with insulin, are known
to be associated with an increased risk for hypoglycemia
and appear to have been used routinely in this study.
Hypoglycemia not requiring medical assistance is not
trivial however. In these cases a substantial reduction of
cognitive and motor function as well as sympathetic
counterregulation is observed [17].
Weight gain with antidiabetic drugs
A positive correlation between weight gain and glycaemic
control is well known [18]. Inappropriate weight gain has
been demonstrated in landmark diabetes studies with
insulin or oral anti-diabetic drugs [19]. Weight gain is
associated with accelerated deterioration of beta-cell
function in type 2 diabetes, and increases blood pressure
and lipid levels in both type 1 and type 2 diabetes. Con-
cerns about increasing weight may be a barrier to initia-
tion or to intensification of insulin therapy. Insulin
introduction may be delayed in type 2 diabetes, and
patients may under-dose insulin to avoid weightgain [20].
Costs
There are only three studies on the costs of diabetes in
Germany [21-23]: In the CODE-2 Study (Costs of Dia-
betes in Europe-Type 2) the total expenses for type 2
diabetes were evaluated [22]. The costs per patient -
compared to the average expenses for health insured
patients - increased with complication state from the
1.3-fold (no complications) up to the 4.1-fold (macro-
and microvascular complications). The second study
was the CoDiM (Cost of Diabetes Mellitus) study
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high costs associated with the care of diabetic patients
could be largely attributed to inpatient care and overall
medication costs. The third study was the German
multi-centre, retrospective epidemiological cohort study
ROSSO [21]. Total costs of diabetes care was 1,288 €
for the first treatment year with diagnosed diabetes and
rose to 3,845 € in year seven. Costs for treating compli-
cations dominated already in the first year after diagno-
sis. The mean direct treatment costs amounted to 3,210
€ per patient and year for the first 6.5 years.
Rationale
Treatment decisions in primary diabetes care are pri-
marily based on evidence from randomized controlled
trials. These trials however are confined by strict in-
and exclusion criteria and patients seen in daily practice
differ from the ones documented in clinical trials. In
this respect the advantage of registries is to document a
variety of patient types and physicians’ treatment deci-
sions without influence imposed by the study design.
Therefore the external validity of findings in respect to
real life conditions is usually high.
With respect to the disease and treatment related com-
plications outlined, we think it is utmost important to gain
an understanding of what the patient characteristics are,
which disease related laboratory values patients have, what
co-morbid diseases are present, what treatment options
are used and which complications (e.g. cardiovascular
events, hypoglycemia, weight gain) occur during the
course of treatment. It is further important to gain an
understanding of patient self reported outcomes (PRO)
such as treatment satisfaction and health status.
Methods
Diabetes Treatment Patterns and Goal Achievement in
Primary Diabetes Care (DiaRegis) is a prospective,
observational, national, multicenter registry with a fol-
low-up of 2 years conducted in Germany. Data were
recorded at baseline and will be prospectively documen-
ted during follow up visits at 6 ± 1, 12 ± 2 and 24 ±
2 months.
This registry is conducted in accordance with the ethi-
cal principles that have their origin in the Declaration of
Helsinki and adhere to the principles of Good Epide-
miology Practice (GEP), and applicable regulatory
requirements. The protocol of this registry was approved
by the ethics committee of the Landesärztekammer
T h ü r i n g e ni nJ e n a ,G e r m a n yo nM a r c h4
th 2009.
Patients that were enrolled into this registry provided
written informed consent. It was further registered with
the database of the Verband forschender Arzneimittel-
hersteller (VFA) [25].
Research Question/Hypothesis
The aim of the present registry is to evaluate the speci-
fic characteristics, treatment patterns, quality of life and
diabetes related events of type-2 diabetic patients who
Figure 1 Intensified treatment has been associated with an increase in the rate of hypoglycemia [4-6].
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Page 3 of 14failed oral mono- or dual antidiabetic therapy and physi-
cians deemed a change of therapy to be necessary.
Because of the increasing risk of hypoglycemia after
intensifying antidiabetic treatment when achieving near
normal blood glucose values, we chose as a primary
objective of DiaRegis to determine the proportion of
patients with at least 1 episode of severe hypoglycemia
within one year.
Secondary objectives were: 1) To evaluate the number of
patients with at least 1 episode of severe, moderate or
mild hypoglycemia after 1 and 2 years respectively; 2) To
evaluate the number of hypoglycaemic events per patient
after 1 and 2 years, respectively; 3) To evaluate the glycae-
m i cp r o f i l e ;4 )T oe v a l u a t eac h a n g ei nm e a s u r e db o d y
weight over the course of the study; 5) To evaluate fasting
blood glucose and postprandial glucose of patients; 6) To
evaluate the health status (EQ-5D) and treatment satisfac-
tion (DTSQ); 7) To evaluate co-morbid disease conditions;
8) To determine costs associated with hypoglycemia; 9)
To determine costs associated with therapy/treatment and
disease related complications.
Definitions
Hypoglycemia was classified as follows. In case of severe
hypoglycemia the patient seeks medical attention or is
admitted to hospital because of hypoglycemia. In case of
moderate hypoglycemia patients experience symptoms
of hypoglycemia and require assistance from a second
person (a relative or friend, etc.), but no medical atten-
tion is necessary. Mild hypoglycemia is determined from
blood glucose measurements (< 2.22 mmol/l; 40 mg/dl
in any case; 2.22-2.78 or 50 mg/dl in case of symptoms)
and is manageable without foreign help.
Physician selection
Physicians have been selected based on a conditioned
random sampling method. For this purpose a physician
database with about 9.350 office based physicians
(general practitioners, internists, practitioners and diabe-
tologists) who treat patients with type 2 diabetes were
asked in writing, to evaluate the possibility of participa-
tion. For this purpose physicians were requested to
complete a questionnaire to check on whether they fulfil
criteria for participation. Only physicians with at least
150 patients with type 2 diabetes under regular medical
care were eligible to ensure, that a broad treatment
spectrum will be covered and to secure that physicians
were able to recruit patients fast and efficient and to
receive a random distribution across all German regions.
The sampling strategy should thus provide a representa-
tive dataset for the description of oral antidiabetic treat-
ment patterns in Germany.
Physicians were contacted once and informed about
the background and aims of the study. They were asked
to complete a fax questionnaire indicating their eligibil-
ity and consent to participate in the study (or to give a
reason for non-participation). The response further
included site information about personal data as well as
equipment of the site, especially with respect to the reg-
istry requirements. Non-participants will be assessed for
comparability with participating physicians regarding
physician and office characteristics.
1-2 weeks prior to the study, participating physicians
received detailed information material, physician and
patient questionnaires and access to a secure website for
the entry of patient documentation. A telephone hotline
was provided by the CRO and by the Institut für
Herzinfarktforschung.
Patient selection
Inclusion Criteria were as follows: 1) Patients with type-
2d i a b e t e s ;2 )A g e≥ 40 years; 3) The treating physician
indicated that blood glucose lowering therapy needed to
be stepped up or changed, e.g. because glycaemic targets
were not met or medication not safe and/or not toler-
ated; 4) Oral mono- or dual combination therapy (no
insulin/no GLP-1 analogue); 5) The physician actually
added another drug/switches therapy; 6) Provision of
patient informed consent.
The following exclusion criteria applied: 1) Patients
not under regular supervision of the treating physician
for the duration of the study; 2) Patients with type 1
diabetes; 3) Pregnancy (gestational diabetes); 4) Diabetes
secondary to malnutrition, infection or surgery; 5)
Maturity onset diabetes of the young; 6) Known cancer
or limited life expectancy; 7) Further reasons for exclu-
sion were conditions that made it impossible or highly
problematic for the patient to participate and to come
to the follow-up visits (such as poor German language
skills, serious disabilities or diseases, hospitalization) and
acute emergencies; 8) Participation in a clinical trial.
The following subgroups are pre-defined and will be
further explored: 1) patients that are prescribed insulin
(with or without OAD) as the next step; 2) patients that
are prescribed any combination with a DPP-4 inhibitor;
3) patients that are prescribed a combination of metfor-
min and sulfonylureas; 4) patients that are prescribed a
combination of metformin and a thiazolidinedione; 5)
patients that are prescribed a combination of sulfonyur-
eas and a thiazolidinedione; 6) patients that are pre-
scribed any other combination including those receiving
a GLP-1 analogue/mimetic.
Documented variables
Table 1 gives an overview of variables obtained during
regular visits at baseline and during follow-up including
those from the physicians and patient questionnaires.
Figure 2 illustrates the study design. Further to these
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mentation of hypoglycaemic events (date, measured
blood glucose, severity of hypoglycemia, glucagon use)
during the 2 year follow-up.
Monitoring
To reduce the logistics of coordinating such a nation-
wide study, participating physicians received no other
instructions than the information material sent to them
by mail prior to the survey. Further they were contacted
within a few days prior to commencement of the study
to ensure compliance with the registry protocol. To con-
trol for a proper procedure and to ensure the robustness
of the data obtained, a specifically adapted monitoring
system was designed to meet the logistic needs. This
monitoring concept included telephone and fax moni-
toring and random on-site visits. The monitors were
specifically trained prior to start of the study, especially
in terms of survey procedures and criteria for follow-up
appointments.
On-site visits were performed within the month fol-
lowing the recruitment into the registry, with a focus on
quality of data and measurements. Monitoring visits are
conducted in at least 10% of the participating sites
randomly selected. Monitoring is split into 4 parts sug-
gesting to monitor 3% of the sites (n = 13) after enrol-
ment of patients, 3% after 6 months (n = 13), 2% after
12 months (n = 9) and 2% after 24 months (n = 9). The
observed quality problems and errors at the monitored
sites allow an estimation of the overall error rate of the
study. For every site monitored selected patient data
were to be checked for integrity and compared with the
source data. The physician or physician assistants were
requested to rectify observed errors.
Database Methodology
Data entry was performed by the physician or study
nurse via a secure website directly into an electronic
database. This approach allowed online checks for plau-
sibility and integrity.
Data from the patient questionnaire (paper version)
which was asked to be completed by the patient during
the visit were transferred to the CRO appointed. The
questionnaires were scanned and transferred to the
Institut für Herzinfarktforschung for evaluation.
All data sets were checked for incorrect data and cor-
rected if applicable; all corrections are documented. All
data sets are submitted for biostatistic analysis.
Table 1 Study flow chart
Evaluation Observational Phase
Month M0 M6 (± 1 M) M12 (± 2 M) M24 (± 2 M)
Demographics & Co-morbidity
Inclusion/Exclusion Criteria X
Patient Identification X X X X
Date of visit X X X X
Date of consent X
Demographics X
Physical examination X X X X
Diabetes history X
Diabetic complications and co-morbidity X X X X
Pharmacotherapy X X X X
Laboratory values:
TC, TG, HDL-C, LDL-C X X X X
Serum-Creatinine, Micro-, Macroalbuminuria X X X X
CRP X X X X
HbA1c, FPG, PPG X X X X
Non-drug intervention X X X X
Hypoglycaemic events X X X X
Body Weight
Body weight and height X X X X
Hip and waist circumference X X X X
EQ-5D, DTSQ X X X
Hypoglycemia Awareness Questionnaire X X X X
WHO-5 X X X
TC, total cholesterol; TG, triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycosylated haemoglobin A1c; CRP, C-reactive protein;
FPG, fasting plasma glucose; PPG, post-prandial glucose; EQ-5D, EuroQol-5D; DTSQ, Diabetes Treatment Satisfaction Questionnaire; WHO, World Health
Organization
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Descriptive statistics (mean, standard deviation, range,
percentiles, proportions etc.) are calculated for all
patients and the pre-specified subgroups. Chi square
tests or Wilcoxon rank sum tests are used where appro-
priate to investigate differences in distributions of vari-
ables by subgroups. Multivariable analyses are
conducted as necessary to adjust for other covariates.
All statistical analyses are conducted using the statistical
software package SAS 9.1 (SAS Institute, Cary, NC,
USA).
The analysis is planned to: 1) Describe the baseline
patient characteristics, including risk factors, co-morbid-
ity, pharmacotherapy received, switching between thera-
peutic options and a number of PRO measures; 2)
Estimate the incidence and frequency of hypoglycaemic
events after 1 and after 2 years, as well as changes in
PRO measures at each visit; 3) Analyse any associations
between the choice of pharmacotherapy and outcomes
after 1 and after 2 years; 4) Identify independent deter-
minants of hypoglycaemic events using multivariable
statistics.
A specific objective of DiaRegis is to estimate the cost
of hypoglycemia. Therefore it will consider the number
of patients with events and the number of events per
patient.
Sample Size
The primary objective for sample size consideration is to
estimate the proportion of patients with at least 1 epi-
sode of severe hypoglycemia within one year. Based on
recently reported rates of severe hypoglycaemic events
between 0.4% and 3.1% per year, a conservative estima-
tion of the overall rate of severe hypoglycaemic events
of 1.5% over 1 year and a desirable precision of the esti-
mate of ± 0.337% the sample size had to be 5000
patients. In case of a reduced recruitment of 3,900
patients or 3,600 patients an estimate precision of
± 0.382% and ± 0.397% was expected.
Results
313 primary care offices included patients into DiaRegis.
109 were general practitioners, 116 diabetologists, 84
internists and 4 others (Figure 3). Between June 2009
Figure 2 Graphical study design. M, month(s); FU, follow-up; D, Day; FPG, fasting plasma glucose; PPG, post-prandial glucose; EQ-5D, EuroQol-
5D; DTSQ, Diabetes Treatment Satisfaction Questionnaire
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Page 6 of 14Figure 3 Regional distribution of participating practices throughout Germany (as of 30.04.2010).
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Page 7 of 14and March 2010 these physicians included a total of
4,048 patients. Of these 238 patients were excluded
because in- and exclusion criteria were not met, includ-
ing 7 patients who withdrew informed consent. There-
fore 3810 patients out of 313 practices were available
for the description of baseline patient characteristics
(Figure 4).
Patient characteristics and laboratory values at baseline
Of the 3810 patients available for the baseline analysis
46.7% were female; patients had median diabetes dura-
tion of 5.5 years and most were obese with respect to
BMI or waist circumference. HbA1c at baseline was
7.4%, fasting plasma glucose 142 mg/dl and postprandial
glucose 185 mg/dl (for further baseline characteristics
see Table 2). In comparison men were slightly younger,
and had higher blood glucose values (HbA1c, fasting and
postprandial glucose) along with significant differences
in lipid values (p < 0.0001).
Risk factors and co-morbid conditions at baseline
11.9% of patients were smoking and 62.9% were drink-
ing any alcohol (men > women; p < 0.0001; Table 3).
On the other hand more men were doing any sports
even if seldom (45.0 vs. 34.6%; OR 1.55; 95%CI 1.35-
1.78). While the prevalence of coronary artery disease
(23.4 vs. 11.7%; OR 2.31; 95%CI 1.93-2.76) and myocar-
dial infarction (38.9 vs. 24.1% of those with CAD; OR
2.00; 95%CI 1.38-2.92) was higher in men than in
women, clinical evidence of relevant depression (indi-
cated by the treating physician) was less frequent
in men (3.6 vs. 7.4%; OR 0.47; 95%CI 0.35-0.63;
p < 0.0001).
Drug utilization
68.6% of patients received oral monotherapy, 31.4% dual
oral combination therapy. The most frequent antidia-
betic agent used in monotherapy was metformin (79.0%)
followed by sulfonylureas (14.8%) (Figure 5, panel A).
Figure 4 Patient flow chart. OAD, oral antidiabetic drugs
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Page 8 of 14In patients with dual oral combination therapy the most
frequent combinations were metformin with sulfonylur-
eas (55.8%), glitazones (15.5%), DPP-4 inhibitors (12.6%)
and glinides (8.6%), respectively (Figure 5, panel B). Dif-
ferences between male and female patients were negligi-
ble and not significant except for a slightly more
frequent use of glinides in men (10.1 vs. 6.8%; p < 0.05).
At the inclusion visit patients’ oral antidiabetic agents
were either adjusted, added, substituted for another oral
antidiabetic agent or insulin or a GLP-1 analogue was
added. Being asked which reason led to this decision the
physicians indicated that not meeting blood glucose tar-
gets was the most frequent reason (86.9%). Hypoglyce-
mia, weight gain, adverse events and unclassified
reasons were much less important (Figure 6, panel A).
After therapy change the use of sulfonylureas was
slightly reduced (26.3 vs. 28.9%), while the use of DPP-4
inhibitors increased significantly (38.8 vs. 4.9%). Newly
introduced were GLP-1 analogous (9.2%) and insulin
(17.3%) (Figure 6, panel B). Antidiabetic drug therapy
was not statistically different between men and women
at baseline. After therapy change only the use of metfor-
min (85.6 vs. 83.3%; OR 1.19; 95%CI 1.00-1.42) and
glitazones (11.6 vs. 8.8%; OR 1.35; 95%CI 1.09-1.67) was
higher in men.
Discussion
DiaRegis is a large prospective registry evaluating dis-
ease and treatment related complications in patients
with type-2 diabetes in Germany. These data
Table 2 Patient characteristics and laboratory values at baseline
Total (n = 3,810) Men (n = 2,033) Women (n = 1,777) p-value (m vs. f)
Age (years) 65.9 (57.6-72.9) 64.7 (56.8-72.0) 67.2 (58.6-74.1) < 0.0001
Diabetes duration (years) 5.5 (2.9-9.4) 5.5 (2.8-9.3) 5.6 (3.0-9.4) n.s.
BMI (kg/m
2) 30.0 (27.0-35.0) 30.0 (27.0-34.0) 31.0 (28.0-36.0) < 0.0001
Waist circumference (cm) 106 (98-116) 108 (100-118) 104 (95-114) < 0.0001
Total cholesterol (mg/dl) 205 (177-232) 199 (172-228) 211 (185-236) < 0.0001
HDL-Cholesterol (mg/dl) 47 (40-57) 44 (38-52) 52 (44-61) < 0.0001
LDL-Cholesterol (mg/dl) 120 (98-145) 116 (93-142) 123 (103-147) < 0.0001
Triglycerides (mg/dl) 176 (127-243) 184 (129-266) 169 (125-228) < 0.0001
HbA1c (mg/dl) 7.4 (6.8-8.3) 7.5 (6.9-8.4) 7.3 (6.8-8.1) < 0.0001
Fasting plasma glucose (mg/dl) 142 (119-171) 144 (121-175) 140 (118-168) < 0.01
Postprandial glucose (mg/dl) 185 (155-221) 189 (159-225) 179 (151-216) < 0.0001
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycosylated haemoglobin A1c
Table 3 Risk factors and co-morbid conditions at baseline
Total (n = 3,810) Men (n = 2,033) Women (n = 1,777) OR (95%CI) p-value
Smoker 11.9 14.4 9.1 1.69 (1.37-2.08) < 0.0001
Any alcohol, even rare 62.9 79.9 43.6 5.15 (4.38-6.06) < 0.0001
Any Sports, even rare 40.1 45.0 34.6 1.55 (1.35-1.78) < 0.0001
Dyslipidemia 63.3 64.7 61.6 1.14 (1.00-1.31) < 0.05
Hypertension 84.4 83.6 85.3 0.88 (0.74-1.05) n.s.
Malignancy 2.0 1.8 2.2 0.83 (0.52-1.30) n.s.
Coronary artery disease 17.9 23.4 11.7 2.31 (1.93-2.76) < 0.0001
Prior MI 34.4 38.9 24.1 2.00 (1.38-2.92) < 0.001
Prior stroke/TIA 4.6 5.0 4.2 1.18 (0.87-1.60) n.s.
PAD 6.0 7.7 4.1 1.95 (1.46-2.60) < 0.0001
Amputation* 0.9 1.2 0.6 2.20 (1.05-4.60) < 0.05
Heart failure 9.9 10.4 9.3 1.13 (0.91-1.40) n.s.
Autonomous neuropathy 3.4 3.7 2.9 1.28 (0.89-1.84) n.s.
Symptoms of peripheral neuropathy 14.4 15.7 12.8 1.27 (1.06-1.53) < 0.05
NPDR 3.8 3.6 3.9 0.91 (0.65-1.28) n.s.
PDR 0.5 0.5 0.5 0.97 (0.39-2.40) n.s.
Blindness 0.2 0.2 0.2 1.17 (0.26-5.22) n.s.
Clinically relevant depression 5.4 3.6 7.4 0.47 (0.35-0.63) < 0.0001
PDR, proliferative diabetic retinopathy; MI, Myocardial Infarction; NPDR, non-proliferative diabetic retinopathy; PAD, peripheral arterial disease; TIA, transitory
ischemic attack; OR, odds ratio; CI, confidence interval; * toe, foot or lower extremity
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Page 9 of 14Figure 5 Drug utilization in DiaRegis of patients on oral monotherapy (68.6% of all patients) (panel A) and on dual oral combination
therapy (31.4%of all patients) (panel B).
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Page 10 of 14Figure 6 Reason for a change of pharmacotherapy at baseline (panel A) and choice of drugs thereafter (panel B).
Bramlage et al. Cardiovascular Diabetology 2010, 9:53
http://www.cardiab.com/content/9/1/53
Page 11 of 14supplement evidence obtained from randomized con-
trolled trials by documenting drug use in specific
patient populations, concomitant diseases, concurrent
pharmacotherapies and are thus highly relevant for daily
practice.
Need for a prospective observational registry
There are a number of epidemiological studies which
documented (among other aspects) the treatment of
type-2 diabetes. Table 4 gives an overview about stu-
dies closely related to the research question of DiaRe-
gis. These included the 2001 HYDRA study [26], the
2003 DETECT study [27] and the studies CODE-2
[22,28,29], ROSSO [21,30], DUTY [31], CoDiM [23]
and DIG [32,33]. These have aimed at describing the
situation of diabetic patients in primary care in Ger-
many. Finally SWEETHEART is a prospective registry
in patients with type-2 diabetes and acute myocardial
infarction with or without ST elevation within the pre-
vious 24 h. It started in October 2006 and included
2,772 patients in 31 hospitals in Germany but results
have been presented [34] but not published yet.
Most of these studies however either had a detailed
look on the prevalence of type-2 diabetes in primary
care practice (HYDRA and DETECT), the co-morbidity
burden (DETECT), the costs (CODE-2, CoDiM and
ROSSO), on self-monitoring of blood glucose (ROSSO)
or on the effect of tailored intervention on target
achievement (DUTY, DIG). Most of these did not con-
sider nutritional/dietary aspects, as well as a more custo-
mized approach to the recruited patients’ lifestyle and
physical activity [35,36]. Some were also retrospective in
design (CODE-2, CoDiM and ROSSO). Moreover most
epidemiological studies are rather old, and contempor-
ary data are scarce [32,33].
The particular value of DiaRegis relates to the pro-
spective evaluation of antidiabetic therapy in patients
being prone to disease and treatment related complica-
tions such as hypoglycaemia. The prospective design
will improve data quality in comparison to other regis-
tries because a structured assessment and documenta-
tion is usually more complete and consistent than
retrospective analyses of existing data which have been
obtained for other purposes. With this respect the
monitoring concept in this registry is important (tables
4 and 5), in that the validation of data with the respec-
tive source data will further improve data quality. This
has previously been shown to be effective in other
registries [37,38].
Conclusions
DiaRegis is a large, prospective registry in primary dia-
betes care to document the course and outcomes of
patients with type-2 diabetes who failed the initial
approach of oral mono/dual antidiabetic therapy. The
two year follow-up will allow for a prospective evalua-
tion of these patients during multiple adjustments of
therapy. The results of this registry will help to under-
stand how the degree of diabetes control and treat-
ment-related events such as hypoglycemia or diabetes-
related complications impact patient reported out-
comes. It further might give insight in how to improve
patient care in type 2 diabetes with the ultimate goal
to improve outcomes and possibly prolong life.
Table 4 Comparison of DiaRegis with other existing registries (part I)
DiaRegis CODE-2 CoDiM ROSSO
Reference [22] [23,24] [21]
No. of physicians 313 135 n.a. 192
No. of patients 3,810 809 26,971 3,286
Recruitment 06/2009-03/2010 1 year (1998) 2001 1995-2003
Follow-up 2 years none none Min. 4 years
Design Prospective cohort Retrospective, cross-
sectional
Database analysis Retrospective cohort
Monitoring for
data verification
Yes (10%) None None None
Proportion T2D 100% 100% 100% 100%
Patients Patients on oral mono- or dual
antidiabetic combination therapy
Patients with type-2
diabetes mellitus
Patients with type-2
diabetes mellitus
Patients with newly diagnosed
type-2 diabetes mellitus
Median age (years) 65.9 66 n.a. Mean 62.5 ± 9.6
Female (%) 46.7 52 n.a. 51.4
BMI (median) 30.0 28 n.a. Mean 29.8 ± 5.1
Focus Hypoglycemia incidence with
antidiabetic drug use
Costs of type-2
diabetes
Costs of diabetes Costs of diabetes
n.a., not available
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